

Oncopeptides to present at the Jefferies London Healthcare Conference on November 14th

Stockholm – October 12, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies London Healthcare Conference on November 14th at 3.20 PM local time (GMT), the presentation will be webcasted.

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate melflufen (Ygalo[®]), an alkylating peptide, belongs to a novel class of peptidase-enhanced compounds (PEnCs), intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma.

Melflufen (Ygalo[®]) has been used to treat late-stage RRMM patients in the phase II clinical study called O-12-M1 that is completed with favorable results which have been reported previously. Currently, Oncopeptides conduct four clinical trials with melflufen for the treatment of multiple myeloma. These are HORIZON, OCEAN, ANCHOR and BRIDGE.

The current clinical study program is intended to demonstrate better results from treatment with melflufen (Ygalo[®]) compared to established alternative drugs for patients with late-stage multiple myeloma. This could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

For further information, please contact:

Rein Piir, Head of Investor Relations at Oncopeptides AB
E-mail: rein.piiir@oncopeptides.com

This information was submitted for publication at 09.00 CET October 12, 2018

About Oncopeptides

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate melflufen (Ygalo[®]), an alkylating peptide, Peptidase Enhanced Compounds (PEnCs). Melflufen (Ygalo[®]) is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from treatment with melflufen (Ygalo[®]) compared with established alternative drugs for patients with late-stage multiple myeloma. Melflufen (Ygalo[®]) will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Visit www.oncopeptides.se for more information.